Form 8-K - Current report:
SEC Accession No. 0001708599-25-000065
Filing Date
2025-07-01
Accepted
2025-07-01 16:02:25
Documents
14
Period of Report
2025-07-01
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ser-20250701.htm   iXBRL 8-K 28237
2 EX-99.1 ex991_serina-pressrelease2.htm EX-99.1 10569
6 image_0.jpg GRAPHIC 24502
  Complete submission text file 0001708599-25-000065.txt   196414

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20250701.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20250701_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20250701_pre.xml EX-101.PRE 13059
16 EXTRACTED XBRL INSTANCE DOCUMENT ser-20250701_htm.xml XML 2917
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38519 | Film No.: 251096228
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)